MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET

Tumor Biology

Volumn 36, Issue 9, 2015, Pages 6715-6723

  Han, Chao ^a   Zhou, Yubing ^a   An, Qi ^a   Li, Feng ^a   Li, Duolu ^a   Zhang, Xiaojian ^a   Yu, Zujing ^a   Zheng, Lili ^a   Duan, Zhenfeng ^b   Kan, Quancheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Gastric cancer; miR 1; Non coding RNA; Target therapy; Tumor suppressor gene

Indexed keywords

MICRORNA 1; SMALL INTERFERING RNA; UNTRANSLATED RNA; MET PROTEIN, HUMAN; MICRORNA; MIRN1 MICRORNA, HUMAN; SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER CELL; CANCER GRADING; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MET GENE; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RNA DEGRADATION; STOMACH CANCER; STOMACH TUMOR; TISSUE MICROARRAY; WESTERN BLOTTING; WOUND HEALING; BIOSYNTHESIS; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84947125666     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3358-6     Document Type: Article

References (40)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol: WJG. 2006;12(3):354–62.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
4. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102–14.
5. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11(4):441–50.
6. Tomaselli S, Panera N, Gallo A, Alisi A. Circulating miRNA profiling to identify biomarkers of dysmetabolism. Biomark Med. 2012;6(6):729–42.
7. Chan EK, Ceribelli A, Satoh M. MicroRNA-146a in autoimmunity and innate immune responses. Ann Rheum Dis. 2013;72 Suppl 2:ii90–5.
8. Wu CD, Kuo YS, Wu HC, Lin CT. MicroRNA-1 induces apoptosis by targeting prothymosin alpha in nasopharyngeal carcinoma cells. J Biomed Sci. 2011;18:80.
9. Li D, Yang P, Li H, Cheng P, Zhang L, Wei D, et al. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. Life Sci. 2012;91(11–12):440–7.
10. Han C, Yu Z, Duan Z, Kan Q. Role of microRNA-1 in human cancer and its therapeutic potentials. BioMed Res Int. 2014;2014:428371.
11. Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer. 2011;104(2):235–40.
12. Tominaga E, Yuasa K, Shimazaki S, Hijikata T. MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. Exp Cell Res. 2013;319(3):77–88.
13. Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(3):737–47.
14. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 2012;40(8):3689–703.
15. Yoshino H, Enokida H, Chiyomaru T, Tatarano S, Hidaka H, Yamasaki T, et al. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res Commun. 2012;417(1):588–93.
16. Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem. 2009;284(43):29596–604.
17. Duan Z, Choy E, Nielsen GP, Rosenberg A, Iafrate J, Yang C, et al. Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res: Off Publ Orthop Res Soc. 2010;28(6):746–52.
18. Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, et al. miRNA signature associated with outcome of gastric cancer patients following chemotherapy. BMC Med Genet. 2011;4:79.
19. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47(5):784–91.
20. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(8):2269–77.
21. Liu Y, Li Q, Zhu L. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 2012;98(1):105–12.
22. Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 2012;84(4):e525–31.
23. Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, et al. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013;19(3):710–20.
24. Wang K, Zhuang Y, Liu C, Li Y. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Arch Biochem Biophys. 2012;526(1):38–43.
25. Oh YM, Song YJ, Lee SB, Jeong Y, Kim B, Kim GW, et al. A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. Mol Cells. 2012;34(6):523–9.
26. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012;9(6):314–26.
27. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res MCR. 2012;10(4):504–15.
28. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68(15):6162–70.
29. Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, Majumder S, et al. Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 2008;68(13):5049–58.
30. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008;283(48):33394–405.
31. Osaka E, Yang X, Shen JK, Yang P, Feng Y, Mankin HJ, et al. MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. J Orthop Res: Off Publ Orthop Res Soc. 2014;32(8):1075–82.
32. Letelier P, Garcia P, Leal P, Alvarez H, Ili C, Lopez J, et al. Roa JC: miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin Exp Pathol. 2014;7(5):1849–67.
33. Wei W, Hu Z, Fu H, Tie Y, Zhang H, Wu Y, et al. MicroRNA-1 and microRNA-499 downregulate the expression of the ets1 proto-oncogene in HepG2 cells. Oncol Rep. 2012;28(2):701–6.
34. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2012;106(2):405–13.
35. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H, et al. miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget. 2011;2(1–2):29–42.
36. Yu QQ, Wu H, Huang X, Shen H, Shu YQ, Zhang B, et al. MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomed Pharmacother = Biomed Pharmacother. 2014;68(2):155–61.
37. Zhao Q, Zhang B, Shao Y, Chen L, Wang X, Zhang Z, et al. Correlation between the expression levels of miR-1 and PIK3CA in non-small-cell lung cancer and their relationship with clinical characteristics and prognosis. Future Oncol. 2014;10(1):49–57.
38. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802–4.
39. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991;10(10):2867–78.
40. Guo T, Yang J, Yao J, Zhang Y, Da M, Duan Y. Expression of MACC1 and c-Met in human gastric cancer and its clinical significance. Cancer Cell Int. 2013;13(1):121.